Clinical trial
VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With…
NCT00320476 · Korean Multiple Myeloma Working Party, Other · Completed
Key facts
| NCT number | NCT00320476 |
|---|---|
| Title | VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates |
| Official title | Velcade®, Thalidomide, Dexamethasone (VTD) Induction Therapy Followed By Melphalan, Prednisone, Thalidomide (MPT) Maintenance As a First Line Treatment For The Patients With Multiple Myeloma Who Are Non-Transplant Candidates |
| Lead sponsor | Korean Multiple Myeloma Working Party, Other |
| Collaborators | Janssen-Cilag Ltd. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Velcade |
| Enrollment | 35 |
| Start date | Apr 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | May 3, 2006 |
| Last update posted | May 6, 2008 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: